To date, aside from four FDA-approved CD19-redirected CAR-T products, one TRBA (Blinatumomab), two humanized mAbs (Tafasitamab and Inebilizumab), and one humanized ADC (Loncastuximab tesirine) have also been granted FDA approval against CD19, which accentuates its potential as one of the most, if not the most, successful target antigens of cancer immunotherapy. This evidence concerns the gene CD19 and cancer.